SG10201408115SA - Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders - Google Patents

Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Info

Publication number
SG10201408115SA
SG10201408115SA SG10201408115SA SG10201408115SA SG10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA
Authority
SG
Singapore
Prior art keywords
tetrahydropyridines
disorders
treatment
related disease
sodium channel
Prior art date
Application number
SG10201408115SA
Inventor
Kumar Ratty Anil
Entzeroth Michael
Original Assignee
Chakra Biotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chakra Biotech Pte Ltd filed Critical Chakra Biotech Pte Ltd
Priority to SG10201408115SA priority Critical patent/SG10201408115SA/en
Priority to JP2017530206A priority patent/JP6493711B2/en
Priority to AU2015355612A priority patent/AU2015355612B2/en
Priority to EP15864987.1A priority patent/EP3226865A4/en
Priority to US15/522,510 priority patent/US10414728B2/en
Priority to PCT/SG2015/050461 priority patent/WO2016089304A1/en
Priority to SG11201701618SA priority patent/SG11201701618SA/en
Publication of SG10201408115SA publication Critical patent/SG10201408115SA/en
Priority to US15/874,592 priority patent/US20180141907A1/en
Priority to JP2019006802A priority patent/JP2019070036A/en
Priority to AU2019284008A priority patent/AU2019284008A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SG10201408115SA 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders SG10201408115SA (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SG10201408115SA SG10201408115SA (en) 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
JP2017530206A JP6493711B2 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridine in the treatment of sodium channel related diseases and disorders
AU2015355612A AU2015355612B2 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
EP15864987.1A EP3226865A4 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
US15/522,510 US10414728B2 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
PCT/SG2015/050461 WO2016089304A1 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
SG11201701618SA SG11201701618SA (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
US15/874,592 US20180141907A1 (en) 2014-12-05 2018-01-18 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
JP2019006802A JP2019070036A (en) 2014-12-05 2019-01-18 Use of tetrahydropyridine in treatment of sodium channel-related disease and disorder
AU2019284008A AU2019284008A1 (en) 2014-12-05 2019-12-20 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201408115SA SG10201408115SA (en) 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Publications (1)

Publication Number Publication Date
SG10201408115SA true SG10201408115SA (en) 2016-07-28

Family

ID=56092099

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201408115SA SG10201408115SA (en) 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
SG11201701618SA SG11201701618SA (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701618SA SG11201701618SA (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Country Status (6)

Country Link
US (2) US10414728B2 (en)
EP (1) EP3226865A4 (en)
JP (2) JP6493711B2 (en)
AU (2) AU2015355612B2 (en)
SG (2) SG10201408115SA (en)
WO (1) WO2016089304A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106431911B (en) * 2016-09-28 2021-05-28 黄石市利福达医药化工有限公司 Preparation and purification method of 4-felbinac

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410746B1 (en) 1999-04-27 2002-06-25 Research Foundation Of State University Of New York, The Metal cataltsts and methods for making and using same
CA2585014A1 (en) * 2004-10-22 2006-05-04 Mark Froimowitz Methylphenidate analogs and methods of use thereof
PL1845780T3 (en) * 2005-01-20 2011-12-30 Ampio Pharmaceuticals Inc Uses of methylphenidate derivatives
US7700798B1 (en) * 2005-06-08 2010-04-20 The Research Foundation Of State University Of New York Erogorgiaene congeners and methods and intermediates useful in the preparation of same
CN101400676A (en) * 2006-03-10 2009-04-01 纽约州州立大学研究基金会 Tropane prodrugs with central nervous system activity

Also Published As

Publication number Publication date
WO2016089304A1 (en) 2016-06-09
US20170355676A1 (en) 2017-12-14
JP2017537113A (en) 2017-12-14
JP2019070036A (en) 2019-05-09
US20180141907A1 (en) 2018-05-24
AU2015355612A1 (en) 2017-06-29
EP3226865A4 (en) 2018-06-06
AU2019284008A1 (en) 2020-01-23
EP3226865A1 (en) 2017-10-11
AU2015355612B2 (en) 2019-10-03
US10414728B2 (en) 2019-09-17
AU2015355612A2 (en) 2019-01-31
SG11201701618SA (en) 2017-03-30
JP6493711B2 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
IL265590B (en) Keratin treatment formulations and methods
IL269174A (en) Methods for treating complement-mediated diseases and disorders
IL254142B (en) Tradipitant for use in the treatment of a tradipitant-responsive disease or condition
IL249580A0 (en) Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
IL250990A0 (en) Human therapeutic agents
PL3277280T3 (en) Isomyosmine for use in the treatment of autoimmune diseases
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
PT3160464T (en) 6-hydroxybuspirone for use in the treatment of movement disorders
IL246855A0 (en) Agents for use in the treatment of retinal inflammation
GB201418809D0 (en) Therapeutic agents and uses thereof
IL251135A (en) Method for the synthesis of hydroxy-triglycerides and use thereof for the prevention and treatment of diseases
PL3341481T3 (en) Microrna-328 anti-sense composition and therapeutic use
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
HK1252359A1 (en) Combination of trazodone and gabapentin for the treatment of pain
PT3442537T (en) (+)-azasetron for use in the treatment of ear disorders
IL250244A0 (en) Preventing and treating inflammatory skin diseases
GB201419559D0 (en) Therapeutic compositions and methods